5-Methyl-2-(pyrazin-2-yl)-1,3-thiazol-4-yl cyclopropanecarboxylate

Catalog No.: 
ACUSOS535
CAS No.: 
338409-43-1
Molecular Formula: 
C12H11N3O2S
Molecular Weight: 
261.31
5-Methyl-2-(pyrazin-2-yl)-1,3-thiazol-4-yl cyclopropanecarboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg90%$196.00InquiryInquiry
1g90%$563.00InquiryInquiry
5g90%$2759.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Methyl-2-(pyrazin-2-yl)-1,3-thiazol-4-yl cyclopropanecarboxylate
IUPAC Name5-methyl-2-(pyrazin-2-yl)thiazol-4-yl cyclopropanecarboxylate
MDL No.MFCD00172600
Molecular FormulaC12H11N3O2S
Molecular Weight261.31
SMILESO=C(C1CC1)OC2=C(C)SC(C3=NC=CN=C3)=N2
InChI KeyWUPODGCTGAYQHQ-UHFFFAOYSA-N
Synonym5-methyl-2-(pyrazin-2-yl)-1,3-thiazol-4-yl cyclopropanecarboxylate;5-METHYL-2-(2-PYRAZINYL)-1,3-THIAZOL-4-YL CYCLOPROPANECARBOXYLATE;Cyclopropanecarboxylic acid, 5-methyl-2-(2-pyrazinyl)-4-thiazolyl ester
CAS No.338409-43-1

Synthetic Route by SureRoute

1. ACUSOS535 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUSOS535 route product structure diagram
    ACUSOS535338409-43-1
Inquiry

2. ACUSOS535 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUSOS535 route product structure diagram
    ACUSOS535338409-43-1
Inquiry

3. ACUSOS535 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUSOS535 route product structure diagram
    ACUSOS535338409-43-1
Inquiry

Comments (0)